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ABSTRACT
Background. Many individuals together in semi-confined settings increase the risk of outbreaks of infec-
tious diseases. A single case of varicella on a cruise ship can thus result in rapid spread and elevated costs
for the cruise provider in terms of repatriation, ship diversion, law suits, and loss in current and potential
future revenue. Control of varicella involves attention to good personal hygiene, safe food and water han-
dling, and use of vaccine.
Objectives. To test crewmembers during their pre-employment medical examination to determine who
might be susceptible to contract varicella if exposed, to vaccinate those at risk, and to see whether the
benefits of testing and vaccination outweigh the costs.
Material and methods. Tests were conducted on 121 Indian seafarers for varicella IgG and IgM antibo-
dies during their pre-employment medical examination in Mumbai and Goa from December 1st to Decem-
ber 23rd 2008. Cases without IgG antibodies to varicella (IgG negative) were administered vaccine.
Results. Twenty (16.5%) seafarers who tested IgG negative and one who tested equivocally were adminis-
tered the vaccine. One hundred (82.7%) tested positive for IgG antibodies and were therefore not vaccina-
ted. None tested positive for IgM antibodies, indicating no active infection.
Conclusions. One in six Indian seafarers tested IgG negative and was thus at risk to contract varicella if
exposed. Testing for varicella IgG and IgM antibodies, followed by vaccination when necessary, is a cost-
effective method to prevent an expensive outbreak in the semi-confined setting of a cruise ship and is
recommended as a mandatory part of the pre-employment medical examination for Indian seafarers.

 INTRODUCTION
“Emporiatrics” is the modern term coined to describe
the science and health of travellers. The word actually comes
from the Greek emporos, meaning “one who goes onboard
a ship as a passenger,” and iatrike, meaning “medicine”
[1]. Travel by sea is one of the earliest forms of transporta-
tion. According to the Cruise Line International Association,
an estimated 12 million North Americans took a cruise in
2006 (www.cruising.org/press/overview2008). These large
cruise ships can serve as a gathering place or a melting
pot, so to speak, for the global community, where passen-
gers and crew from around the world bring together a diver-
sity of cultures, as well as medical and immunizational back-
grounds and health risk behaviours. Cruise voyages can last
from several hours (gambling cruises) to several months
(around the world and semester-at-sea cruises); however,
the average duration of cruise travel is about seven days.
This time period permits ample opportunities for passen-
gers and crew (medical personnel included) to come into
repeated and prolonged contact through shared activities,
such as games and dining, and through resources such as
food and water, resulting in opportunities for exposure and
www.intmarhealth.pl 33
Nikhil Idnani, Varicella among seafarers: a case study on testing and vaccination as a cost-effective method of prevention
transmission of communicable diseases. In addition, as
cruise ships make multiple port stops, where differences in
sanitation standards may exist as well as disease exposure
risks, embarking passengers and crew can import and
spread communicable diseases on board.
One such infectious disease (varicella or chickenpox) is
caused by the varicella zoster virus (VZV). It is a highly con-
tagious illness caused by primary infection with the varicel-
la zoster virus. It generally begins with a vesicular skin rash
appearing in two or three waves, mainly on the body and
head rather than the hands, and becoming itchy raw pock-
marks — small open sores which heal mostly without scar-
ring. Chickenpox has a 10–21 day incubation period and is
spread easily through aerosolized droplets from the na-
sopharynx of ill individuals or through direct contact with
secretions from the rash. Following primary infection there
is usually lifelong protective immunity from further episodes
of chickenpox. Chickenpox is rarely fatal, although it is ge-
nerally more severe in adults than in children. Pregnant wom-
en and those with a suppressed immune system are at high-
est risk of serious complications. The most common late
complication of chicken pox is shingles, caused by reactiva-
tion of the varicella zoster virus decades after the initial
episode of chickenpox [2]. An outbreak of an infectious dis-
ease such as varicella on board a semi-confined space like
a cruise ship can therefore lead to large scale damage. The
aims of this study was to test crewmembers during their
pre-employment medical examination to determine who
might be susceptible to contract varicella if exposed, to vac-
cinate those at risk, and to see whether the benefits of test-
ing and vaccination outweigh the costs.
MATERIAL AND METHODS
CASES
The subjects used in this study were 121 Indian seafar-
ers employed on cruise ships, consecutively undergoing their
pre-employment medical examination (PEME) at two loca-
tions in India — Mumbai (Colaba) and Goa (Porvorim) — be-
tween December 1st and December 23rd 2008. All were
young males between the ages of 21 and 42 years and were
employed in the lower ranks of assistant waiter, snack ste-
ward, security guard, etc. Proper consent for testing was
obtained from all.
BLOOD TESTING
Blood was drawn by venepuncture, using routine precau-
tions, and collected in a Vacutainer containing a clot activa-
tor gel. The separated serum was tested the same day for
antibodies to varicella IgG and IgM, simultaneously, using
Varicella-Zoster-Virus IgM ELISA and VIDAS Varicella Zoster
IgG testing kits (Biomerieux Inc., USA) [3]. Proper handling
and storage of all test materials was done according to the
testing kit literature to maintain accuracy. Positive anti-IgG
test indicates immunity towards varicella, so positive cases
were not to be vaccinated or retested. Positive anti-IgM test
indicates active infection, and such cases were to be retes-
ted in four weeks for anti-IgG, and if still found negative, were
to be vaccinated. However, positive anti-IgM cases were ex-
pected to turn anti-IgG positive on retesting as the active in-
fection causes the development of anti-IgG antibodies to va-
ricella. Cases that tested negative for anti-IgG and anti-IgM
were to be administered the vaccine.
VACCINATION
After ruling out all contraindications listed on the vac-
cine product information, all anti-IgG negative cases were
administered the VARILRIX vaccine (Glaxo-Smith-Kline phar-
maceuticals, Australia) [4]. VARILRIX is a lyophilized prepa-
ration of the live attenuated Oka strain of varicella-zoster
virus, obtained by propagation of the virus in MRC5 human
diploid cell culture. Each 0.5 ml dose of the reconstituted
vaccine contains not less than 103.3 plaque-forming units
(PFU) of the varicella-zoster virus. The vaccine also contains
amino acids, human albumin, lactose, neomycin sulphate,
and polyalcohols. VARILRIX meets the World Health Organi-
zation requirements for biological substances and for vari-
cella vaccines [4].
VARILRIX was administered as a single dose by subcuta-
neous injection after reconstitution, and the upper arm (del-
toid region) was the preferred site of injection. No major ad-
verse events were reported to vaccination beside the usual
minor rash, fever, etc. The date of the first dose was marked
on a vaccination card and the cases were instructed to re-
port back after six weeks to receive the second dose or, if
travelling at that time, to take the second dose at their place
of convenience. A record of vaccination was kept for future
reference. The varicella vaccine has been reported to be mod-
erately effective in adults with some cases still not acquiring
immunity even after vaccination [5, 6]. However, this was
the best-known method of prevention of varicella.
The cost per IgG test and per vaccine was obtained to
perform at a cost-benefit analysis.
RESULTS
Out of the 121 cases, 20 (16.5%) seafarers who tested
IgG negative and one who tested equivocally were adminis-
tered the vaccine. One hundred (82.7%) tested positive for
IgG antibodies and were therefore not vaccinated. None of
the cases tested positive for IgM antibodies, indicating no
active infection. This indicates that 100 crew members ei-
ther had the disease earlier or had been vaccinated. From
the history given by these 100 crew members, about 25
thought they might have had chicken pox during childhood,
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while another 35 thought they had been vaccinated against
the disease, but the recollection was uncertain and these
numbers could not be trusted.
Of the 20 cases that tested negative, none recalled vac-
cination or disease, but this information was also unreli-
able.
At an approximate cost of USD 50 per test, the total cost
of testing was around USD 6,000. Additionally, at an average
cost of USD 40–50 for 2 doses of the vaccine, the cost
of vaccination of the 20 IgG negative cases was approximately
USD 800–1000. This would bring the total cost of testing
and vaccination in this sample to a little over USD 7,000.
DISCUSSION
Infections can be life threatening for seafarers and pas-
sengers on cruise ships and can lead to major costs and di-
sruption for maritime employers (owners, stakeholders, man-
ning agents). Preventive measures are therefore essential.
Detecting and preventing the spread of infectious diseases
during cruises is important not only to protect the health of
cruise travellers but also to avoid global dissemination of dis-
eases in home communities through disembarking passen-
gers and crew members [7, 8]. Where large numbers of sus-
ceptible passengers are carried, as on cruise ships, outbreaks
of infectious diseases such as chicken pox, can be severe,
and crew immunization should be considered.
In the present study, 100 seafarers tested positive, but
few of them remembered having had chickenpox or being
vaccinated. This highlights the fact that one cannot rely
solely on the medical history given by crew members. Test-
ing is therefore a more accurate way to determine their im-
mune status. (Revised, from Results)
From the above results, it can be seen that there is
a moderately important large number of crew members in the
study who tested ‘negative’ for the varicella IgG test, display-
ing poor or no immunity to the VZV. This cohort of the popu-
lation is at clear risk of contracting chickenpox when exposed
to the virus in a closed population, or during an epidemic.
The method of prevention that we advocate here is vaccina-
tion with the varicella live attenuated vaccine to develop im-
munity in these crew members. Testing 121 Indian seafar-
ers and vaccinating the 21 that tested negative for varicella
cost a little more than USD 7,000. If testing and vaccination
were not carried out, and if even 1 out of the 20 cases that
tested negative, acquired varicella, and spread it to a hand-
ful of other crew members and passengers, the total cost of
on-board treatment, quarantine, repatriation, ship diversion,
law suits, etc. would clearly result in expenses far higher than
USD 7,000, as well as significant loss in current and poten-
tial future revenue. Thus prevention benefits outweigh costs
even for a disease with a low incidence rate. Vaccination is
one method of prevention. Other methods of prevention
should also be considered in individuals at risk of serious
disseminated varicella infection, i.e. the immunocompro-
mised, pregnant women, and neonates. Immunocompro-
mised individuals should be advised to avoid contact with
people with varicella or zoster. If contact has been made,
prophylaxis with passive immunization or antiviral chemo-
therapy should be considered. Heightened disease surveil-
lance efforts by cruise lines in cooperation with public health
authorities and awareness among cruise ship travellers have
led to the detection of illnesses of potential public health
significance that might otherwise have gone unnoticed [9,
10]. Communicable diseases occurring onboard cruise ships
reflect similar onshore events, but transmission risk is en-
hanced by the crowded semi-closed cruise ship environment,
with increased opportunities for interpersonal interaction
[11]. In addition, an estimated one third of cruise travellers
are senior citizens who, along with travellers with underlying
chronic health problems, are at increased risk of morbidity
from infectious agents [12–16]. Health professionals wor-
king on board cruise ships should also be tested and fully
immunized, including confirmed protection from laboratory
testing. Ship operators and employers have a duty to protect
the health and safety of their workers as well as their clien-
tele (the passengers). In practical terms, implementing this
general duty of care means that they are responsible for
minimizing the risks of infection by advocating preventive
measures such as immunizations.
In conclusion, 16.5% of Indian seafarers tested Varicel-
la IgG negative. Testing for IgG and IgM antibodies against
varicella, followed by vaccination when necessary, is a cost-
-effective method to prevent an expensive outbreak in the
semi-confined setting of a cruise ship and is recommended
as a mandatory part of the pre-employment medical exa-
mination for Indian seafarers.
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